GSK announces EU submission seeking additional indication for Votrient® as maintenance therapy for advanced ovarian cancer
6 August 2013 | By GlaxoSmithKline
“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline..."


















